Akademik Veri Yönetim Sistemi
Clinical cancer research : an official journal of the American Association for Cancer Research, cilt.25, sa.13, ss.3996-4013, 2019 (SCI-Expanded)
Purpose: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are currently used in combination with endocrine therapy to treat advanced hormone receptor-positive, HER2-negative breast cancer. Although this treatment doubles time to progression compared with endocrine therapy alone, about 25%-35% of patients do not respond, and almost all patients eventually acquire resistance. Discerning the mechanisms of resistance to CDK4/6 inhibition is crucial in devising alternative treatment strategies.